BIO-Europe 2007 Draws Record Crowd Of Biotech And Pharmaceutical Industry Leaders

Main Category: Pharma Industry / Biotech Industry
Also Included In: Conferences
Article Date: 16 Nov 2007 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Over 2000 leaders from the biotechnology and pharmaceutical industry gathered this week for the 13th Annual BIO-Europe 2007 International Partnering Conference. The conference was held in Hamburg, Germany on November 12-14 and was co-organized by the EBD Group and the Biotechnology Industry Organization (BIO), in partnership with European Biopharmaceutical Enterprises.

The conference included 19 interactive workshops, panel discussions, international seminars and company presentations. The Opening Plenary focused on the anticipated convergence between biotech and the pharmaceutical industry. Panelists discussed the opportunity for biologics to enable pharmaceutical companies to achieve greater market share, as well as overlaps and convergence between biotech and Big Pharma.

"This year's BIO-Europe was the largest held to date with over 2200 delegates. This highly successful event brought together biotech and pharmaceutical industry leaders from around the globe to develop partnerships, share insights on business trends, and discuss policy issues and other factors that impact the biotech industry," said Jim Greenwood, President and Chief Executive Officer of BIO.

Attendees came from around the world to participate in over 8500 partnering meetings geared toward exploring mutually beneficial deals. A Plenary Session entitled, "A Day in the Life of Experienced Dealmakers," [http://www.ebdgroup.com/bioeurope/] featured leading dealmakers highlighting recent case studies and discussing the externalization of research and development, trends within mergers and acquisitions and licensing opportunities.

BIO-Europe 2007 has exceeded expectations with over 2,200 delegates. The priority for all conference delegates is sitting down with potential partners to discuss projects for licensing, molecules, financing and other collaborative programs. "This is the key to the success we are seeing today," said Carola Schropp, Managing Partner, EBD Group. "The success of BIO-Europe sets the stage for an exciting and productive BIO-Europe Spring® partnering conference in Madrid, Spain, April 7-9, 2008".

About EBD Group

EBD Group International, LLC is the leading partnering firm for the global biotechnology industry. Since 1993, firms in the life sciences have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business. EBD Group's conferences (run in collaboration with leading industry partners and international trade associations such as the Biotechnology Industry Organization (BIO) include BIO-Europe (co-organized with BIO), the preeminent stand-alone or ex-U.S. partnering conference for the biotechnology industry; BIO-Europe Spring; the investor conference, BioEquity Europe (co-organized with BioCentury Publications and BIO); and the convergent medical technology partnering conference, BioDevice Partnering. EBD's novel, web-based, partnering software system is also used at numerous third-party events around the world. Outside of the conference format, EBD Group's consultants can provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in San Diego, Munich and London.

http://www.ebdgroup.com

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the global event for biotechnology.

http://www.bio.org